Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready
Aardvark Therapeutics Inc. currently has 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. This level of activity indicates a steady effort to protect the company's pharmaceutical intellectual property through a focused prosecution strategy.
The portfolio is distributed among a matching number of distinct examiners and 4 distinct art units. This distribution means that every one of the 4 pending office actions is being reviewed by a different specialist in a separate specialized unit of the patent office, requiring a strategy that accounts for various procedural styles.
AGGARWAL, SAHIL CHANDER is the busiest examiner, currently overseeing 1 pending office action. Because each of the distinct examiners is responsible for only one matter, no single examiner's tendencies will have a disproportionate impact on the overall portfolio's success in the Biotechnology & Pharmaceuticals sector. Practitioners must remain adaptable to the specific requirements of these 4 distinct art units to ensure favorable outcomes.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| Multi-statute (no §101) | 3 (75%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AGGARWAL, SAHIL CHANDER | 1 | 66.7% | +0.0% |
| OH, TAYLOR V | 1 | 81.3% | +15.3% |
| HIBBERT, CATHERINE S | 1 | 58.8% | +48.6% |
| IVANOVA, SVETLANA M | 1 | 50.9% | +51.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18924880 | Abuse-Deterrent Pharmaceutical Composition with Aversion Properties | AGGARWAL, SAHIL CHANDER | — |
| 18631587 | Monohydrate Salt of Denatonium Acetate | OH, TAYLOR V | — |
| 18557182 | COMBINATION OF BITTER RECEPTOR AGONIST AND GUT-SIGNALING COMPOUND | HIBBERT, CATHERINE S | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17845399 | Pharmaceutical Composition for Treatment or Prevention of Multiple Inflammatory disorders | IVANOVA, SVETLANA M | 60d overdue |
| 18631587 | Monohydrate Salt of Denatonium Acetate | OH, TAYLOR V | — |
| 18557182 | COMBINATION OF BITTER RECEPTOR AGONIST AND GUT-SIGNALING COMPOUND | HIBBERT, CATHERINE S | — |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| 1625 | 1 |
| 1658 | 1 |
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18924880 | Abuse-Deterrent Pharmaceutical Composition with Aversion Properties | AGGARWAL, SAHIL CHANDER | 1623 | §102§103§112 | Non-Final OA | — | Pending | Oct 23, 2024 |
| 18631587 | Monohydrate Salt of Denatonium Acetate | OH, TAYLOR V | 1625 | §102§103 | Final Rejection | — | Pending | Apr 10, 2024 |
| 18557182 | COMBINATION OF BITTER RECEPTOR AGONIST AND GUT-SIGNALING COMPOUND | HIBBERT, CATHERINE S | 1658 | §102§103§112 | Non-Final OA | — | Pending | Oct 25, 2023 |
| 17845399 | Pharmaceutical Composition for Treatment or Prevention of Multiple Inflammatory disorders | IVANOVA, SVETLANA M | 1627 | §103 | Non-Final OA | 60d overdue | Pending | Jun 21, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAardvark Therapeutics Inc. has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Sahil Chander Aggarwal has the most, with 1 of Aardvark Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
